secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2024-04-10T23:59:59+00:00
Accession:  0001437749-24-011571
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 1.02, 2.03, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Therapeutics closes $100M senior secured loan facility; repays prior debt
-------------------------------------------------------------------------------

- Secured $100M loan; $60M funded, $20M available later, $20M contingent on FDA approval of arimoclomol for Niemann-Pick disease Type C.
- Interest rate is 3-month SOFR plus 7.00% (floor 4.00%); steps down to 6.00% or 6.50% based on net product sales thresholds.
- Proceeds refinanced Nantahala note (repaid April 8, 2024), pay fees, and fund Olpruva and arimoclomol development/commercialization.
- Loan matures 5 years from April 5, 2024; prepayment premiums and final payment premium of 3% of initial principal apply.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924011571/0001437749-24-011571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924011571/zvra20240409_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-011571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer